TY - JOUR
T1 - Lifetime ovulatory years and risk of epithelial ovarian cancer
T2 - a multinational pooled analysis
AU - on behalf of the Ovarian Cancer Association Consortium
AU - on behalf of the AOCS Group
AU - Fu, Zhuxuan
AU - Brooks, Maria Mori
AU - Irvin, Sarah
AU - Jordan, Susan
AU - Aben, Katja K.H.
AU - Anton-Culver, Hoda
AU - Bandera, Elisa V.
AU - Beckmann, Matthias W.
AU - Berchuck, Andrew
AU - Brooks-Wilson, Angela
AU - Chang-Claude, Jenny
AU - Cook, Linda S.
AU - Cramer, Daniel W.
AU - Cushing-Haugen, Kara L.
AU - Doherty, Jennifer A.
AU - Ekici, Arif B.
AU - Fasching, Peter A.
AU - Fortner, Renée T.
AU - Gayther, Simon A.
AU - Gentry-Maharaj, Aleksandra
AU - Giles, Graham G.
AU - Goode, Ellen L.
AU - Goodman, Marc T.
AU - Harris, Holly R.
AU - Hein, Alexander
AU - Kaaks, Rudolf
AU - Kiemeney, Lambertus A.
AU - Köbel, Martin
AU - Kotsopoulos, Joanne
AU - Le, Nhu D.
AU - Lee, Alice W.
AU - Matsuo, Keitaro
AU - Mcguire, Valerie
AU - Mclaughlin, John R.
AU - Menon, Usha
AU - Milne, Roger L.
AU - Moysich, Kirsten B.
AU - Pearce, Celeste Leigh
AU - Pike, Malcolm C.
AU - Qin, Bo
AU - Ramus, Susan J.
AU - Riggan, Marjorie J.
AU - Rothstein, Joseph H.
AU - Schildkraut, Joellen M.
AU - Sieh, Weiva
AU - Sutphen, Rebecca
AU - Terry, Kathryn L.
AU - Thompson, Pamela J.
AU - Titus, Linda
AU - Van Altena, Anne M.
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Background: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. Results: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. Conclusions: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
AB - Background: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. Results: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. Conclusions: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
UR - http://www.scopus.com/inward/record.url?scp=85151251586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151251586&partnerID=8YFLogxK
U2 - 10.1093/jnci/djad011
DO - 10.1093/jnci/djad011
M3 - Article
C2 - 36688720
AN - SCOPUS:85151251586
SN - 0027-8874
VL - 115
SP - 539
EP - 551
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 5
ER -